Belotecan, new camptothecin analogue, is active in patients with small-cell lung cancer: results of a multicenter early phase II study
- Authors
- Lee, D. H.; Kim, S. -W.; Suh, C.; Lee, J. -S.; Lee, J. H.; Lee, S-J.; Ryoo, B. Y.; Park, K.; Kim, J. S.; Heo, D. S.; Kim, N. K.
- Issue Date
- 1월-2008
- Publisher
- OXFORD UNIV PRESS
- Keywords
- belotecan; single agent; small-cell lung cancer
- Citation
- ANNALS OF ONCOLOGY, v.19, no.1, pp.123 - 127
- Indexed
- SCIE
SCOPUS
- Journal Title
- ANNALS OF ONCOLOGY
- Volume
- 19
- Number
- 1
- Start Page
- 123
- End Page
- 127
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/124458
- DOI
- 10.1093/annonc/mdm437
- ISSN
- 0923-7534
- Abstract
- Background: Belotecan (Camtobell (R), Chong Keun Dang Corp, Seoul, Korea; CKD602) is a new camptothecin analogue. This study aimed to investigate the safety and efficacy of single-agent belotecan for small-cell lung cancer (SCLC). Patients and methods: Twenty-seven patients with chemotherapy-naive or chemosensitive SCLC were treated with belotecan 0.5 mg/m(2)/day on days 1-5 of a 3-week cycle. All 27 patients were assessable for toxicity, and 21 patients assessable for response. Results: Nine patients (42.9%) showed objective tumor responses including one complete response; seven (63.6%) in 11 chemotherapy-naive patients; and two (20.0%) in 10 chemosensitive patients. With a median follow-up of 5 years, median progression-free and survival time for chemotherapy-naive patients were 4.8 months and 11.9 months, respectively, while the corresponding values for chemosensitive patients were 3.3 months and 10.5 months, respectively. The most common toxicity was neutropenia. Conclusion: Belotecan was active in SCLC patients as a single agent, warranting further investigations of belotecan in combination with platinum or other active agents.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Medical Science > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.